• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小肠神经内分泌肿瘤患者原发性肿瘤切除的手术及肿瘤学结局:一项单中心15年系列研究结果

Surgical and Oncologic Outcomes of Primary Tumor Resection in Patients with Small Intestinal Neuroendocrine Tumors: Results from a Single-Center Series Over a 15-Year Period.

作者信息

Danieli Maria, Fumagalli Romario Uberto, Radice Davide, Pozzi Simonetta, Spada Francesca, Funicelli Luigi, Fazio Nicola, Bertani Emilio

机构信息

University of Milan, Milan, Italy.

Division of Digestive Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

出版信息

Ann Surg Oncol. 2025 Mar;32(3):2141-2149. doi: 10.1245/s10434-024-16588-9. Epub 2024 Dec 3.

DOI:10.1245/s10434-024-16588-9
PMID:39627636
Abstract

BACKGROUND

The role of prophylactic primary tumor resection (PTR) in patients with small intestinal neuroendocrine tumors (SI-NETs) and unresectable liver metastases is a matter of debate.

OBJECTIVE

We aimed to evaluate outcomes in patients with SI-NETs who underwent PTR, according to the presence of metastasis and symptoms from primary.

MATERIAL AND METHODS

Data from patients who underwent PTR for SI-NETs from a single referral center (2007-2023) were prospectively collected. Patients were divided into three groups: non-metastatic (M0) and metastatic with primary tumor-related symptoms (MS) or metastatic asymptomatic (MA). Kaplan-Meier curves for overall survival (OS) and event-free survival (EFS) were generated and compared by group. Univariate and multivariable Cox regression analyses were performed to assess the significance of risk factors.

RESULTS

Of 147 patients, 53 were M0, 23 were MS, and 71 were MA. Median follow-up was 26 months. The 5- and 10-year OS estimates were 100% and 100% in M0 patients, 82 and 21% in MS patients, and 89 and 80% in MA patients, respectively (p < 0.001). Median EFS was 91 months overall and 43,126 months and not reached for the MS, MA, and M0 groups, respectively (p < 0.001). In multivariable analysis, MS (hazard ratio [HR] 3.92, 95% confidence interval [CI] 1.71-9.52), functioning tumors (HR 1.98, 95% CI 1.03-3.81), and G2 grade (HR 3.20, 95% CI 1.64-6.85) were associated with a shorter EFS.

CONCLUSIONS

In this large retrospective series, the MS group had a significantly worse OS and EFS compared with M0 and MA. This finding suggests that prophylactic PTR might benefit SI-NET patients with unresectable liver metastases, as symptom development could impair long-term prognosis after surgery.

摘要

背景

预防性原发性肿瘤切除术(PTR)在小肠神经内分泌肿瘤(SI-NETs)合并不可切除肝转移患者中的作用存在争议。

目的

我们旨在根据转移情况和原发灶症状,评估接受PTR的SI-NETs患者的预后。

材料与方法

前瞻性收集来自单一转诊中心(2007 - 2023年)接受PTR治疗的SI-NETs患者的数据。患者分为三组:无转移(M0)、有原发肿瘤相关症状的转移患者(MS)或无症状转移患者(MA)。生成总生存(OS)和无事件生存(EFS)的Kaplan-Meier曲线,并按组进行比较。进行单因素和多因素Cox回归分析以评估危险因素的显著性。

结果

147例患者中,53例为M0,23例为MS,71例为MA。中位随访时间为26个月。M0患者的5年和10年OS估计分别为100%和100%,MS患者分别为82%和21%,MA患者分别为89%和80%(p < 0.001)。总体中位EFS为91个月,MS、MA和M0组分别为43、126个月和未达到(p < 0.001)。在多因素分析中,MS(风险比[HR] 3.92,95%置信区间[CI] 1.71 - 9.52)、功能性肿瘤(HR 1.98,95% CI 1.03 - 3.81)和G2级(HR 3.20,95% CI 1.64 - 6.85)与较短的EFS相关。

结论

在这个大型回顾性系列研究中,与M0和MA相比,MS组的OS和EFS明显更差。这一发现表明,预防性PTR可能使合并不可切除肝转移的SI-NETs患者受益,因为症状的出现可能会损害手术后的长期预后。

相似文献

1
Surgical and Oncologic Outcomes of Primary Tumor Resection in Patients with Small Intestinal Neuroendocrine Tumors: Results from a Single-Center Series Over a 15-Year Period.小肠神经内分泌肿瘤患者原发性肿瘤切除的手术及肿瘤学结局:一项单中心15年系列研究结果
Ann Surg Oncol. 2025 Mar;32(3):2141-2149. doi: 10.1245/s10434-024-16588-9. Epub 2024 Dec 3.
2
Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas.原发肿瘤切除术对小肠和胰腺转移性高分化神经内分泌肿瘤治疗的影响。
J Neuroendocrinol. 2024 Aug;36(8):e13399. doi: 10.1111/jne.13399. Epub 2024 May 17.
3
Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.预防性手术治疗 IV 期小肠神经内分泌肿瘤与生存的关系。
JAMA Oncol. 2018 Feb 1;4(2):183-189. doi: 10.1001/jamaoncol.2017.3326.
4
Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.IV 期小肠神经内分泌肿瘤患者的相关预后因素。
J Neuroendocrinol. 2022 Jan;34(1):e13076. doi: 10.1111/jne.13076. Epub 2021 Dec 28.
5
Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.基于 SEER 的分析:原发肿瘤切除术可改善伴肝转移的胃肠胰神经内分泌肿瘤患者的生存。
Cancer Med. 2019 Sep;8(11):5128-5136. doi: 10.1002/cam4.2431. Epub 2019 Jul 22.
6
Modified Histopathological Grading Optimizes Prediction of Survival Outcomes in Small Intestinal Neuroendocrine Tumors.改良的组织病理学分级可优化小肠类癌生存结局的预测。
J Clin Endocrinol Metab. 2024 Nov 18;109(12):e2222-e2230. doi: 10.1210/clinem/dgae111.
7
Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.三级转诊中心治疗小肠神经内分泌肿瘤的长期手术结果。
World J Surg. 2012 Jun;36(6):1419-31. doi: 10.1007/s00268-011-1296-z.
8
Indication for liver transplantation in young patients with small intestinal NETs is rare?小肠神经内分泌肿瘤的年轻患者进行肝移植的指征罕见吗?
World J Surg. 2014 Mar;38(3):742-7. doi: 10.1007/s00268-013-2331-z.
9
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.原发胃肠道神经内分泌肿瘤切除术可改善生存,与是否行肝治疗无关。
Ann Surg. 2019 Dec;270(6):1131-1137. doi: 10.1097/SLA.0000000000002809.
10
Outcomes of Simultaneous Resection of Small Bowel Neuroendocrine Tumors with Synchronous Liver Metastases.同时切除小肠神经内分泌肿瘤和同步肝转移瘤的结果。
World J Surg. 2020 Jul;44(7):2377-2384. doi: 10.1007/s00268-020-05467-5.

引用本文的文献

1
Prognosis of NETs: Has There Been Improvement over the Last 30 Years?神经内分泌肿瘤的预后:在过去30年里有改善吗?
Neuroendocrinology. 2025 May 30:1-13. doi: 10.1159/000546613.
2
ASO Author Reflections: Primary Tumor Resection in Metastatic Small Intestinal Neuroendocrine Tumors: A Step Toward Standardized Management?ASO作者反思:转移性小肠神经内分泌肿瘤的原发肿瘤切除术:迈向标准化管理的一步?
Ann Surg Oncol. 2025 Mar;32(3):2185-2186. doi: 10.1245/s10434-024-16718-3. Epub 2024 Dec 25.

本文引用的文献

1
[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.[吕]吕-DOTA-TATE 联合长效奥曲肽对比高剂量长效奥曲肽治疗新诊断的晚期 2-3 级、高分化胃肠胰神经内分泌肿瘤(NETTER-2):一项开放标签、随机、3 期研究。
Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.
2
Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors.广泛转移的高分化小肠神经内分泌肿瘤患者的原发肿瘤治疗的发病率和结局。
Ann Surg Oncol. 2024 Apr;31(4):2337-2348. doi: 10.1245/s10434-023-14637-3. Epub 2023 Nov 30.
3
European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease.欧洲神经内分泌肿瘤学会(ENETS)2022年类癌综合征和类癌心脏病指南文件。
J Neuroendocrinol. 2022 Jul;34(7):e13146. doi: 10.1111/jne.13146. Epub 2022 May 25.
4
Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors.预测小肠神经内分泌肿瘤患者原发性肿瘤和肠系膜淋巴结肿块的可切除性。
Updates Surg. 2022 Oct;74(5):1697-1704. doi: 10.1007/s13304-022-01251-3. Epub 2022 Feb 27.
5
Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases: A Propensity-score Matched Comparative Population-based Analysis.针对伴有同步转移的小肠神经内分泌肿瘤的 upfront 小肠切除术:一项倾向评分匹配的基于人群的比较分析。
Ann Surg. 2022 Nov 1;276(5):e450-e458. doi: 10.1097/SLA.0000000000004647. Epub 2020 Nov 18.
6
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.原发性肿瘤的先前切除可延长晚期神经内分泌肿瘤肽受体放射性核素治疗后的生存期。
Ann Surg. 2021 Jul 1;274(1):e45-e53. doi: 10.1097/SLA.0000000000003237.
7
The Landmark Series: Neuroendocrine Tumor Liver Metastases.地标系列:神经内分泌肿瘤肝转移。
Ann Surg Oncol. 2020 Sep;27(9):3270-3280. doi: 10.1245/s10434-020-08787-x. Epub 2020 Jul 6.
8
Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).对于存在大量神经内分泌肿瘤肝脏转移(NETLMs)的患者,可实现有效的细胞减灭术。
Surgery. 2019 Jan;165(1):166-175. doi: 10.1016/j.surg.2018.04.070. Epub 2018 Oct 19.
9
Carcinoid Heart Disease: A Review.类癌心脏疾病:综述。
Endocrinol Metab Clin North Am. 2018 Sep;47(3):671-682. doi: 10.1016/j.ecl.2018.04.012.
10
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.原发胃肠道神经内分泌肿瘤切除术可改善生存,与是否行肝治疗无关。
Ann Surg. 2019 Dec;270(6):1131-1137. doi: 10.1097/SLA.0000000000002809.